Top

Published in:

01-02-2011 | Letter to the Editor

Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast

Authors: Eugeni Lopez-Bonet, Maria Carmen Pérez-Martínez, Begoña Martin-Castillo, Miguel Alonso-Ruano, Francesc Tuca, Cristina Oliveras-Ferraros, Sílvia Cufí, Alejandro Vazquez-Martin, Miquel Beltràn, Luis Bernadó, Javier A. Menendez

Published in: Breast Cancer Research and Treatment | Issue 1/2011

Excerpt

To the Editor, …

WHO (2003) World Health Organization classification of tumors. In: Tavassoli FA, Devilee P (eds) Pathology and genetics of tumours of the breast and female genital organs. IARC Press, Lyib, pp 9–112

Günhan-Bilgen I, Zekioglu O, Ustün EE, Memis A, Erhan Y (2003) Neuroendocrine differentiated breast carcinoma: imaging features correlated with clinical and histopathological findings. Eur Radiol 13:788–793PubMed

Kawasaki T, Nakamura S, Sakamoto G et al (2010) Neuroendocrine ductal carcinoma in situ of the breast: cytological features in 32 cases. Cytopathology. (Epub ahead)

Righi L, Sapino A, Marchiò C, Papotti M, Bussolati G (2010) Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol 27:69–76CrossRefPubMed

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed

Weigelt B, Geyer FC, Horlings HM et al (2009) Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 22:1401–1414CrossRefPubMed

Richter-Ehrenstein C, Arndt J, Buckendahl AC et al (2010) Solid neuroendocrine carcinomas of the breast: metastases or primary tumors? Breast Cancer Res Treat 124:413–417CrossRefPubMed

Lopez-Bonet E, Alonso-Ruano M, Barraza G et al (2008) Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep 20:1369–1374PubMed

Bhargava R, Beriwal S, Dabbs DJ (2007) Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity. Am J Clin Pathol 27:103–113CrossRef

10.

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRefPubMed

11.

Caputo E, Manco G, Mandrich L, Guardiola J (2000) A novel aspartyl proteinase from apocrine epithelia and breast tumors. J Biol Chem 275:7935–7941CrossRefPubMed

12.

Sapino A, Righi L, Cassoni P et al (2001) Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women. Mod Pathol 14:768–776CrossRefPubMed

13.

Honma N, Takubo K, Akiyama F et al (2005) Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47:195–201CrossRefPubMed

14.

Esparís-Ogando A, Ocaña A, Rodríguez-Barrueco R et al (2008) Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells. Ann Oncol 19:1860–1869CrossRefPubMed

15.

Bhargava R, Beriwal S, Striebel JM, Dabbs DJ (2010) Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR. Appl Immunohistochem Mol Morphol 18:113–118CrossRefPubMed

16.

Vranic S, Tawfik O, Palazzo J et al (2010) EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod Pathol 23:644–653CrossRefPubMed

17.

Wei B, Ding T, Xing Y et al (2010) Invasive neuroendocrine carcinoma of the breast: a distinctive subtype of aggressive mammary carcinoma. Cancer 116:4463–4473CrossRefPubMed

Title: Diagnostic utility of mammaglobin and GCDFP-15 in the identification of primary neuroendocrine carcinomas of the breast
Authors: Eugeni Lopez-Bonet
Maria Carmen Pérez-Martínez
Begoña Martin-Castillo
Miguel Alonso-Ruano
Francesc Tuca
Cristina Oliveras-Ferraros
Sílvia Cufí
Alejandro Vazquez-Martin
Miquel Beltràn
Luis Bernadó
Javier A. Menendez
Publication date: 01-02-2011
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2011
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-010-1229-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2011

Erratum to: The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study

Interactions between breast cancer cells and bone marrow derived cells in vitro define a role for osteopontin in affecting breast cancer cell migration

Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma

No association of polymorphisms in the cell polarity gene SCRIB with breast cancer risk in German population

Invasive ductal breast cancer associated polymyositis causing respiratory failure

Body weight and risk of breast cancer in BRCA1/2 mutation carriers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer